Advertisement
Advertisement
VTVT
vTv Therapeutics Inc. Class A Common Stock
30.73
USDSponsored
+0.15
+0.49%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
30.73
0.00
0.00%
VTVT Earnings Reports
Positive Surprise Ratio
VTVT beat 23 of 37 last estimates.
62%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.19
Implied change from Q2 26 (Revenue/ EPS)
--
/+13.33%
Implied change from Q3 25 (Revenue/ EPS)
--
/+10.19%
vTv Therapeutics Inc. Class A Common Stock earnings per share and revenue
On Aug 06, 2026, VTVT reported earnings of -1.05 USD per share (EPS) for Q2 26, missing the estimate of -1.00 USD, resulting in a -3.98% surprise. Revenue reached --, compared to an expected 306.00 thousand, with a -100.00% difference. The market reacted with a +0.64% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -1.19 USD, with revenue projected to reach -- USD, implying an increase of 13.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were vTv Therapeutics Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, vTv Therapeutics Inc. Class A Common Stock reported EPS of -$1.05, missing estimates by -3.98%, and revenue of $0.00, -100% below expectations.
How did the market react to vTv Therapeutics Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 0.64%, changed from $34.39 before the earnings release to $34.61 the day after.
When is vTv Therapeutics Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for vTv Therapeutics Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, vTv Therapeutics Inc. Class A Common Stock is expected to report EPS of -$1.19 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.